ReBio

📍 Raisio, Finland🗓 Founded 2015👥 25 employees💰 Last funded Jun 2021
Biotechnology🌐 rebiopharma.com
Website LinkedIn
ReBio Pharma is a pre-clinical stage biotechnology company that has developed SiSu®, a novel, proprietary formulation technology that solves the safety and efficacy challenges other sustained release approaches have been unable to resolve. SiSu® is designed to steadily release effective levels of therapeutics within the eye while safely dissolving once drug release is completed, and can be tuned to the drug, indication, and duration of release required. ReBio Pharma is leveraging Sisu® to create a new franchise to transform the standard of care for the millions of patients around the world living with chronic eye disease. Discover more at www.rebiopharma.com
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
1
Hong Kong SAR
1
Frequently asked questions
Who invested in ReBio?
ReBio has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did ReBio last raise funding?
The most recent investment in ReBio recorded on gritt.io was in June 2021.
When was ReBio founded?
ReBio was founded in 2015.
What industry is ReBio in?
ReBio operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is ReBio based?
ReBio is headquartered in Raisio, Finland.